Geode Capital Management LLC Raises Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Geode Capital Management LLC raised its holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 2.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,679,280 shares of the company’s stock after purchasing an additional 83,274 shares during the quarter. Geode Capital Management LLC owned 1.95% of Lineage Cell Therapeutics worth $3,331,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Defender Capital LLC. grew its stake in shares of Lineage Cell Therapeutics by 0.6% during the 3rd quarter. Defender Capital LLC. now owns 5,002,198 shares of the company’s stock worth $4,528,000 after purchasing an additional 29,223 shares during the period. Raffles Associates LP boosted its holdings in Lineage Cell Therapeutics by 3.4% during the third quarter. Raffles Associates LP now owns 4,507,781 shares of the company’s stock worth $4,081,000 after buying an additional 150,000 shares in the last quarter. State Street Corp increased its holdings in Lineage Cell Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,608,352 shares of the company’s stock valued at $2,361,000 after buying an additional 45,483 shares in the last quarter. MAI Capital Management raised its position in shares of Lineage Cell Therapeutics by 2.2% in the third quarter. MAI Capital Management now owns 1,674,679 shares of the company’s stock worth $1,516,000 after acquiring an additional 35,907 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Lineage Cell Therapeutics by 10.0% during the 2nd quarter. Renaissance Technologies LLC now owns 583,622 shares of the company’s stock worth $582,000 after acquiring an additional 53,022 shares in the last quarter. 62.47% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on LCTX. D. Boral Capital reaffirmed a “buy” rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a report on Friday. HC Wainwright upped their target price on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th.

Lineage Cell Therapeutics Trading Down 6.9 %

Shares of NYSEAMERICAN:LCTX opened at $0.55 on Tuesday. Lineage Cell Therapeutics, Inc. has a 1 year low of $0.48 and a 1 year high of $1.61. The company has a market capitalization of $121.10 million, a PE ratio of -4.58 and a beta of 1.16.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.